Radiopharmaceutical developer Molecular Insight Pharmaceuticals has made a number of senior management appointments.
Current board member Anthony Martin, Ph.D., was named nonexecutive chairman, while interim chairman and CEO John Babich, Ph.D., has been tapped as CEO. Babich will also retain his titles of president and chief scientific officer.
In other moves, Molecular Insight has named Paul Looney as chief operating officer, replacing John McCray. Looney comes to the Cambridge, MA-based firm after serving most recently as chairman, CEO, and president of embolotherapy device developer BioSphere Medical.
Paul Granger has also been appointed vice president and general counsel. He comes to Molecular Insight after a stint as counsel with law firm Greenberg Traurig.
The company has also adopted a shareholder rights plan.
Related Reading
Molecular Insight completes phase II trial for Zemiva, December 23, 2008
Molecular Insight reports Q3 financials, November 13, 2008
Molecular Insight reports positive trial results, November 10, 2008
Molecular Insight installs interim CEO, September 26, 2008
Molecular Insight touts Trofex studies, June 18, 2008
Copyright © 2009 AuntMinnie.com
